<DOC>
	<DOC>NCT02191540</DOC>
	<brief_summary>Phase 3, non-randomized, Multicenter, single arm study to assess efficacy and safety of Abnoba viscum F 20mg in patients with malignant pleural effusion</brief_summary>
	<brief_title>Efficacy and Safety Study of Abnoba Viscum F 20mg in Malignant Pleural Effusion Patients</brief_title>
	<detailed_description />
	<mesh_term>Pleural Effusion</mesh_term>
	<mesh_term>Pleural Effusion, Malignant</mesh_term>
	<mesh_term>Viscum album peptide</mesh_term>
	<criteria>Subject who need the pleurodesis among subjects diagnosed with a mlignant pleural effusion Full lung expansion must be achieved within 12 to 24 hours after drainage Expected survival time of at least 2 months Subject who score 50 or more on the Karnofsky Performance Scale Subjects with previous attempts at pleurodesis with sclerosing agent Subjects with trapped lung or bronchial obstruction Subjects with adverse drug response to mistletoe agents Subjects who have participated in another clinical study other than the present study Subjects who is taking immunesuppressive agents Subjects with medical and psychiatric contraindications for the study drug Subjects who are not allowed to participate in the study by legal requirement Subjects who are not allowed to participate in the study by the Investigator's discretion</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>July 2014</verification_date>
</DOC>